HTS043RTA - Ready-to-Assay™ VPAC1 VIP and PACAP Receptor Frozen Cells

×
×
Price:
$659.00
SKU:
HTS043RTA
Quantity:
Qty:
Description
Other Details
Reviews
Related Products
Product Videos
Warranty
Also Viewed
By Category
  • Product Description

    Vasoactive intestinal peptide (VIP), a 28 amino acid peptide originally isolated by its vasodilation activity, binds to two class B GPCRs, VPAC1 and VPAC2, to exert its functions in the CNS, vasculature, immune system and adrenal medulla (Harmar et al., 1998).  In the immune system, VIP is synthesized by mast cells and lymphocytes, and appears to inhibit inflammation and to shift the immune response toward a Th2 pathway (Delgado et al., 2004).  In the heart, VIP is expressed by nerve fibers, where it modulates heart rate, and coronary blood flow (Henning and Sawmiller, 2001).  Cloned human VPAC1-expressing cell line is made in the Chem-1 host, which supports high levels of recombinant VPAC1 expression on the cell surface and contains high levels of the promiscuous G protein Gα15 to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for agonists, antagonists and modulators at VPAC1.

    Additional Resource :  HTS043RTA091914 Datasheet

  • Find Similar Products by Category

  • Other Details

    Item Unit of Measure: PK
    Contents: Pack contains 2 vials of mycoplasma-free cells, 1 ml per vial. Fifty (50) mL of Media Component.
    Storage: Vials are to be stored in liquid N2. Media Component at 4ºC (-20ºC for prolonged storage).
    Applications: Calcium Flux Assay
    Host Cell: Chem-1, an adherent rat hematopoietic cell line expressing endogenous Gα15 protein.
    Exongenous Gene Expression: VIPR cDNA (Accession Number: NM_004624- see CODING SEQUENCE below) expressed from a proprietary expressed from a proprietary pHS plasmid.
    GMO: This product contains genetically modified organisms.
    Reference 1: 1. Delgado M et al. (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56: 249-290.
    Reference 2: 2. Harmar AJ et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50: 265-270.
    Reference 3: 3. Henning RJ and Sawmiller DR (2001) Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49: 27-37.
×
×